Progress towards a public chemogenomic set for protein kinases and a call for contributions by Drewry, DH et al.
RESEARCH ARTICLE
Progress towards a public chemogenomic set
for protein kinases and a call for contributions
David H. Drewry1*, Carrow I. Wells1, David M. Andrews2, Richard Angell3, Hassan Al-Ali4,5,
Alison D. Axtman1, Stephen J. Capuzzi6, Jonathan M. Elkins7, Peter Ettmayer8,
Mathias Frederiksen9, Opher Gileadi10, Nathanael Gray11,12, Alice Hooper3,
Stefan Knapp13, Stefan Laufer14, Ulrich Luecking15, Michael Michaelides16,
Susanne Mu¨ller13, Eugene Muratov6, R. Aldrin Denny17, Kumar S. Saikatendu18, Daniel
K. Treiber19, William J. Zuercher1, Timothy M. Willson1
1 Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina
at Chapel Hill, Chapel Hill, North Carolina, United States of America, 2 AstraZeneca, Darwin Building,
Cambridge Science Park, Cambridge, United Kingdom, 3 Drug Discovery Group, Translational Research
Office, University College London School of Pharmacy, 29–39 Brunswick Square, London, United Kingdom,
4 Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida, United
States of America, 5 Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School
of Medicine, Miami, Florida, United States of America, 6 Laboratory for Molecular Modeling, Division of
Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina
at Chapel Hill, Chapel Hill, North Carolina, United States of America, 7 Structural Genomics Consortium,
Universidade Estadual de Campinas—UNICAMP, Campinas, Sao Paulo, Brazil, 8 Boehringer Ingelheim
RCV GmbH & Co KG, Vienna, Austria, 9 Novartis Institutes for BioMedical Research, Novartis Campus,
Basel, Switzerland, 10 Structural Genomics Consortium and Target Discovery Institute, Nuffield Department
of Clinical Medicine, University of Oxford, Oxford, United Kingdom, 11 Harvard Department of Biological
Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of
America, 12 Department of Cancer Biology, Dana−Farber Cancer Institute, Boston, Massachusetts, United
States of America, 13 Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences,
and Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Straße 15, Frankfurt
am Main, Germany, 14 Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences,
Eberhard Karls Universita¨t Tu¨bingen, Auf der Morgenstelle 8, Tu¨bingen, Germany, 15 Bayer Pharma AG,
Drug Discovery, Mu¨llerstrasse 178, Berlin, Germany, 16 Oncology Chemistry, AbbVie, 1 North Waukegan
Road, North Chicago, Illinois, United States of America, 17 Worldwide Medicinal Chemistry, Pfizer Inc.,
Cambridge, Massachusetts, United States of America, 18 Global Research Externalization, Takeda
California, Inc., 10410 Science Center Drive, San Diego, California, United States of America, 19 DiscoverX
Corporation,Fremont, California, United States of America
* David.Drewry@unc.edu
Abstract
Protein kinases are highly tractable targets for drug discovery. However, the biological func-
tion and therapeutic potential of the majority of the 500+ human protein kinases remains
unknown. We have developed physical and virtual collections of small molecule inhibitors,
which we call chemogenomic sets, that are designed to inhibit the catalytic function of
almost half the human protein kinases. In this manuscript we share our progress towards
generation of a comprehensive kinase chemogenomic set (KCGS), release kinome profiling
data of a large inhibitor set (Published Kinase Inhibitor Set 2 (PKIS2)), and outline a process
through which the community can openly collaborate to create a KCGS that probes the full
complement of human protein kinases.







Citation: Drewry DH, Wells CI, Andrews DM,
Angell R, Al-Ali H, Axtman AD, et al. (2017)
Progress towards a public chemogenomic set for
protein kinases and a call for contributions. PLoS
ONE 12(8): e0181585. https://doi.org/10.1371/
journal.pone.0181585
Editor: Anette Duensing, University of Pittsburgh
Cancer Institute, UNITED STATES
Received: March 31, 2017
Accepted: July 3, 2017
Published: August 2, 2017
Copyright: © 2017 Drewry et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its supporting information
files.
Funding: Our work was funded by the Eshelman
Institute for Innovation (http://unceii.org/). The
funder (Eshelman Institute for Innovation) provided
support in the form of salaries for authors (DHD,
CIW, ADA, WJZ, TMW), but did not play a role in
the study design, data collection and analysis,
decision to publish, or preparation of the
manuscript. The specific roles of all authors are
Kinases: Important targets, untapped opportunities
Protein kinases are a large family of enzymes that catalyze the transfer of phosphate from ATP
to serine, threonine, and tyrosine residues of their substrate proteins. Protein kinases are
found in all eukaryotes from yeast to mammals. Humans express 518 protein kinase catalytic
domains using the Manning classification.[1] The precise number, however, is a matter of
debate, since a number of the proteins are pseudokinases that lack catalytic activity, some have
been re-characterized as members of other protein families (e.g. bromodomains) and some are
enzymes for non-protein substrates.
Over the course of 20 years of experimentation medicinal chemists have become adept at
synthesizing cell-active kinase inhibitors that target the ATP binding site in the catalytic domain
of these enzymes.[2–4] Coupled with the discovery that protein kinases are involved in almost
every aspect of cell signaling and are often dysregulated in human diseases, these enzymes have
become popular targets for development of drugs. Academic, biotech, and large pharmaceutical
company labs alike have pursued kinase inhibition creatively and diligently. These efforts have
borne fruit, and the FDA has approved over 35 small molecule kinase inhibitor medicines since
the turn of century. Accordingly, protein kinases have proven to be among the most productive
of human gene families for development of targeted therapeutics.[5, 6]
Despite the success of protein kinase drug discovery within the pharmaceutical industry,
much of their therapeutic potential remains untapped. An analysis of peer-reviewed publica-
tions and published patent applications in 2010 revealed that 80% of the protein kinases
remained poorly studied and their roles in human biology were largely undefined.[7] More-
over, the vast majority of kinase medicinal chemistry and experimental data remains firewalled
within company databases or held as proprietary know-how, which means the broader scien-
tific community has limited access to this body of knowledge. We anticipate that a wide range
of human diseases will be amenable to treatment with inhibitors of the currently untargeted
protein kinases and that if a high quality set of tool molecules for all protein kinases were freely
available, it would enable their role in cell signaling to be better understood.[8] Building this
detailed understanding of kinase roles on a genomic scale together as a community will con-
tribute to the validation of useful kinase targets across the kinome. These identified targets can
then be considered for the aggressive pursuit, commitment, and action required to bring new
medicines to patients.
One way to understand the role of a particular kinase is to utilize a chemical probe for the
kinase of interest. Small molecule chemical probes that meet stringent criteria for potency and
selectivity are powerful tools to study the biology of their target proteins in cells.[9] Several
investigators have successfully identified chemical probes for historically understudied protein
kinases. These probes proved useful to understand the role of the specifically targeted kinase
in disease biology. For example, synthesis of a chemical probe for BRAF facilitated the study of
its role in tumorigenesis and eventually led to the development of several anti-cancer drugs.
[10] Likewise, chemical probes for the poorly studied kinases such as ZAK[11], STK16[12],
PLK4[13], and STK33[14] have advanced research in oncology and other diseases. However,
although these probes proved extremely useful, each report also highlights the challenges in
identification of highly selective ATP-competitive inhibitors, which can be resource intensive
given the large number of kinases in the protein family.
Building a set of over 500 highly selective kinase chemical probes will take many, many
years of concerted effort. In addition, the community does not know how to prioritize the
development of individual chemical probes. In what order should we address the remaining
kinome so that we find the best targets first? Is there another, more efficient way to identify
kinase targets that are worth pursuing in more depth?
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Kinase chemogenomics
To expedite kinome-wide target discovery, we have begun construction of a comprehensive
kinase chemogenomic set (KCGS). This practical solution takes advantage of the chemical
connectivity of kinases (cross reactivity of inhibitors), the large numbers of kinase inhibitors
already made by labs around the world (and thus volume of data available), and the ability to
screen practically kinome wide. We call the methodology “kinase chemogenomics” since it
seeks to use a set of small molecule kinase inhibitors to interrogate the biology of all kinase
gene products in cells. Bunnage and Jones recently reviewed the concept and utility of chemo-
genomic libraries.[15] They describe a chemogenomic set as a collection of small molecules
with defined (annotated) and narrow activity. A hit from the testing of such a library in a phe-
notypic screen implies that the annotated targets of that hit are involved in modulation of
the measured phenotype. Our KCGS is being constructed with this exact goal in mind: hits
from the set will point to potential targets driving phenotypic responses in disease relevant
phenotypic assays. These targets then are candidates for follow up experiments such as target
knockdown with CRISPR-Cas9 or RNAi, or chemical probe development (Fig 1). These more
pointed biological studies can add further support to the utility of the identified targets. The
successful interplay between annotated compound sets, phenotypic screening, genetic meth-
ods, and bioinformatics is well documented, and integration leads to new insights on targets
and pathways of interest.[16–23] Herein we describe our progress towards the generation of a
publicly available KCGS, and outline a collaborative plan to complete the set. This collabora-
tive project between industrial and academic scientists will build a comprehensive KCGS com-
posed only of potent, narrow spectrum inhibitors that collectively demonstrate full coverage of
all human protein kinases for which there are assays available at one of the contract research
organizations that offers broad kinome profiling (“the screenable kinome”). A publicly avail-
able comprehensive KCGS will accelerate basic research into the biological function and thera-
peutic potential of hundreds of understudied protein kinases.
The Published Kinase Inhibitor Set (PKIS): KCGS proof of concept
experiments
We released our first kinase chemogenomic set, the Published Kinase Inhibitor Set (PKIS[24]),
to catalyze new academic research on understudied kinases by provision of physical samples of
a large set of kinase inhibitors, along with the annotation detailing kinase inhibitory profiles.
PKIS is a collection of 367 ATP-competitive kinase inhibitors representing 31 diverse chemo-
types.[25] Design of the set capitalized on the fact that ATP-competitive inhibitors often dem-
onstrate activity across multiple kinases. The inhibitors were chosen from molecules that
had been previously published by medicinal chemists at GlaxoSmithKline, but had only been
screened against a limited number of kinases. Screening of PKIS across 232 protein kinases
identified potent inhibitors of kinase targets across the kinome, and showed that this set is
made up of compounds with a range of selectivity profiles. The chemical structures of the in-
hibitors and their associated kinase screening data were placed in the public domain (https://
www.ebi.ac.uk/chembldb/extra/PKIS/) and the set was made widely available to the research
community. Using a web-based request mechanism (https://pharmacy.unc.edu/research/sgc-
unc/request-pkis/) a physical copy of PKIS was distributed to over 200 academic investigators
to support their research.
Sharing the PKIS compounds openly allowed investigators across the scientific community
to query the impact of kinase inhibition in diverse biological contexts. For example, PKIS was
used to identify potential medicinal chemistry starting points and generate ligand bound crys-
tal structures for the understudied GRK family kinases.[26] The GRKs have been implicated in
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Fig 1. Schematic: Utilization of the KCGS. (a) Disease relevant phenotypic screen highlights active
compounds (b) Because all the targets are annotated, active molecules points to potential targets of interest.
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heart failure[27], Parkinson’s disease[28], and multiple myeloma[29]. A PKIS compound was
identified as a potent ligand for the pseudokinase MLKL, and the authors demonstrated that
binding to this pseudokinase inhibited necroptosis.[30] Fifty-three PKIS compounds were
identified with sub-micromolar potency against T. brucei, the protozoan pathogen that causes
human African trypanosomiasis, a devastating disease in the developing world.[31] PKIS was
used in a high content screen investigating axon growth in primary CNS neurons.[32] The
team was able to use the broad inhibitor annotation and phenotypic readouts to develop a
semi-empirical, machine learning algorithm that allowed for generation of testable hypotheses
as to patterns of kinase inhibition that led to neurite outgrowth. Screening of PKIS in a num-
ber of chordoma cell lines identified several different EGFR inhibitors with activity.[33]
Chordoma is a rare bone cancer, and no targeted therapies have been approved for use in
chordoma patients. Identification of a well-studied kinase such as EGFR with drugs on the
market and a number of compounds advancing in the clinic for other cancer indications,
allows for potential repurposing, a faster way to approval. These and other examples[34–44] of
PKIS applications demonstrate the utility of sharing an annotated kinase inhibitor set and con-
vinced us to proceed with the construction of a comprehensive KCGS–one that provides cov-
erage of the currently screenable kinome.
The screenable human kinome
As an important step in building a comprehensive KCGS we sought to define the readily
screenable human kinome—those protein kinases for which a robust assay is available through
a commercial vendor. We only counted assays for wild type human protein kinases and
excluded assays for mutant protein kinases, lipid kinases and sugar kinases (Table in S1 Table).
The ten commercial vendors surveyed were Carna Biosciences, DiscoverX, Eurofins, Luceome,
MRC PPU, Nanosyn, ProQinase, Reaction Biology Corp., SignalChem and ThermoFisher.
The commercial protein kinase assays are run in multiple formats, but all have been widely
used by the kinase research community to measure kinase inhibitor activity and selectivity
across a wide range of human kinases.[45] Of the total kinome, we identified 436 kinases for
which there were commercially available assays. Many of the kinases for which no assay was
available have been classified as pseudokinases[46] (Fig 2A). Of course, the absence of a con-
tract research organization assay for a particular kinase does not mean that the kinase in ques-
tion is not assayable, and in fact there are assays for some pseudokinases. Non-overlapping
assays from only two vendors (Fig 2B) provides efficient profiling of the candidate inhibitors
against 97% of the screenable human kinome. Importantly, for more than half of the screen-
able kinome (260 kinases), one can choose from up to seven different vendors, and this offers
flexibility in terms of assay format, custom panel options, data visualization tools, and practical
considerations such as turnaround time and pricing structure.
Progress towards a comprehensive KCGS
Our ideal KCGS will contain 1000–1500 compounds. This number of compounds is on the
order of what many disease relevant phenotypic screens can handle efficiently. In addition, we
conducted a simulation (see methods section for further detail) to estimate the theoretical
number of compounds required to achieve kinome coverage under the selectivity criteria set
forth herein. The simulation suggested that on the order of 570 compounds was sufficient to
(c) Follow up experiments can be used to help confirm importance of these highlighted targets (d) Body of
evidence implicates kinases that can be inhibited to impact disease.
https://doi.org/10.1371/journal.pone.0181585.g001
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achieve a set with all the desired attributes. Thus 1000–1500 compounds well-selected com-
pounds can meet our goal of full kinome coverage and will be able to provide at least two to
four distinct chemotypes (structural classes) inhibiting each kinase.
Fig 2. The screenable protein kinome. Using assays from 10 vendors a total of 436 unique non-mutant human protein kinases can be readily screened.
(a) Subfamily representation of the protein kinases that were not available through the 10 vendors. Nearly half of the unscreenable human kinome is
composed of pseudokinases (b) Histogram illustrating how many vendors can be used to screen across the kinome. For example, there are 43 kinases
that all 10 vendors have screens for (“all” bar). There are another 109 kinases screened by 9 out of 10 vendors (“9/10” bar). There are 38 kinases that only
1 out of the 10 vendors has assays for (“1/10” bar). Note: Our definition of the “screenable kinome” is those kinases for which there is a commercial assay
that can be accessed. It is likely that assays could indeed be configured for many of the kinases not currently on this list.
https://doi.org/10.1371/journal.pone.0181585.g002
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In kinase medicinal chemistry, different chemotypes that target the same kinase often have
different off-target kinase profiles. When two or more chemotypes that inhibit a given kinase
are active in a phenotypic screen, one gains confidence that the phenotypic activity is linked to
that target kinase. Ideally, the compounds included in the KCGS will potently inhibit at least
one kinase with an IC50 value less than 100 nM, and each compound in the set will have potent
activity on less than 4% of the kinome. We will avoid inclusion of even moderately promiscu-
ous compounds (inhibiting >10% of the screenable kinome). Promiscuous compounds do not
aid in the deconvolution (target identification) of phenotypic screening results. Experimental
results from a set of narrow spectrum kinase inhibitors, however, can help scientists focus on
the kinase or sets of kinases that are driving the phenotypic response of interest. The compre-
hensive KCGS will be built from PKIS compounds, PKIS2 compounds (described below),
appropriate literature compounds, and donations from consortium members. In the following
section we describe each of these pieces in turn. It is important to note that the compounds in
KCGS may or may not be suitable for in vivo use. In vivo activity is not a component of the
design criteria. Many of the compounds that end up in KCGS will have been published previ-
ously, so some details on solubility, metabolism, or other properties relevant for in vivo experi-
ments may be available for some set members.
PKIS compounds suitable for inclusion: As mentioned above, PKIS was developed as a first
generation, proof-of-concept KCGS. PKIS compounds have a range of selectivity profiles, with
some members of the set being broad spectrum, thus too promiscuous for inclusion in our
KCGS. Because of this, we have defined criteria for a narrow spectrum inhibitor to be suitable
as a member of the comprehensive KCGS (Box 1, and more detail in the methods section).
Based on current data, 131 compounds from PKIS have useful potency and narrow spectrum
inhibition profiles, and these compounds represent 22 different chemotypes and cover a total
of 58 kinases (Table in S2 Table).
PKIS2 compounds suitable for inclusion: Building on the success of PKIS, we assembled a
second kinase chemogenomic set (PKIS2), composed of 645 small molecule inhibitors repre-
senting 86 diverse chemotypes that were published by medicinal chemists at GlaxoSmithKline,
Pfizer, and Takeda. PKIS and PKIS2 have only nine chemotypes in common. The PKIS2 com-
pounds that are members of these nine chemotypes are not duplicates of PKIS compounds,
but rather expand on the structural variety within the chemotype. Herein we report the com-
position of PKIS2 and broad kinome screening data for these compounds. We profiled PKIS2
Box 1. Criteria for kinase chemogenomic set inclusion.
PKIS:
Potency: At least 1 kinase inhibited >90% Inhibition and one of these selectivity criteria
must also be met:
GINI:> 0.75
Entropy:< 1.65
Selectivity index: SI(90) < 0.02
If only GINI is met then the inhibitor must not inhibit more than 7 kinases above 90%I
for KCGS set inclusion
PKIS2:
Potency–At least 1 kinase with Kd < 100nM
Selectivity index–SI(65) < 0.04
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in singlicate at a concentration of 1 μM against a broad panel of 392 wild-type human kinases
using competitive displacement of diverse immobilized inhibitors as a measure of the activity
of a compound on each specific kinase.[47] The resulting kinome-wide profiling data showed
tight distribution of highly selective compounds (Fig 3). 357 compounds that demonstrated
significant activity on<4% of human wild type kinases were selected for confirmatory Kd
determinations on 339 kinases. Specifically, we generated Kd values for all compounds with
Selectivity Index (SI(65)) < 0.04 against those kinases that showed>80% I. The selectivity
index is a measurement that represents the fraction of kinases inhibited above 65% inhibition
at a 1uM screening concentration. This fraction can range from zero for a compound that
inhibits none of the kinases tested at the chosen threshold to one for a compound that inhibits
all of the kinases tested above the chosen threshold. We chose 0.04 (representing inhibition of
only 4% of the kinases screened) as our selectivity threshold in order to ensure only narrow
spectrum inhibitors were identified. This threshold could be gradually increased to identify
more compounds that may be suitable for the KCGS, but as the threshold goes up the number
of kinases targeted by the inhibitor will rise. The Kd values that were determined based on this
threshold of 0.04 can be found in S3 Table. The high confirmation rate of the Kd determina-
tions demonstrated that the initial broad kinase screen had <0.5% false positive rate despite
being run in singlicate.
In addition, 90% of the confirmed actives demonstrated a Kd <1 μM at one or more
kinases. All chemical structures and wild type kinase profiling data are available in S4 Table.
Applying our potency and selectivity criteria for inclusion in the comprehensive KCGS,
174 PKIS2 compounds (S5 Table) from 23 chemotypes have narrow spectrum activity on 81
kinases.
Fig 3. Selectivity profile of PKIS2 compounds using DiscoverX KINOMEscan. Selectivity Index analysis of PKIS2. 357
compounds demonstrate an SI(65) of <0.04 at 1 μM, and thus inhibit less than 4% of the kinases in this screening panel with more
than 65% inhibition at the 1 μM screening concentration.
https://doi.org/10.1371/journal.pone.0181585.g003
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Due to the differences in screening platforms (Nanosyn for PKIS and DiscoverX for PKIS2),
we utilized different KCGS inclusion criteria for each set. PKIS was screened against a smaller
panel of kinases than PKIS2 so we decided to use stricter selectivity criteria for PKIS compound
selection. Experience indicates that as the number of kinase targets screened grows, additional
kinases will be inhibited. Thus we chose SI(90) at a 1 μM screening concentration for PKIS ver-
sus the SI(65) at 1 μM for PKIS2. Based on this analysis of the screening data we have for PKIS
and PKIS2 compounds, these two sets contain potent and narrow spectrum compounds for 122
non-overlapping kinases. This represents coverage of 28% (122/436) of the screenable kinome.
Literature compounds suitable for inclusion: With a goal of complementing PKIS/PKIS2,
we surveyed the peer-reviewed literature for kinase inhibitors with activity on the existing
gap kinases. This search was done in a non-automated manner, and thus it is likely there are
high quality compounds we have not identified yet. Inhibitors were selected if the literature
reported potency <100 nM activity on a gap kinase and if the compound appeared to display a
suitable narrow spectrum profile through screening against at least 20 (ideally many more)
other protein kinases. The selectivity element of this literature analysis is complicated by the
wide variety of screening strategies utilized, with variation in compound screening concentra-
tion, composition of assay panel, assay format, and amount and detail of profiling data actually
shared in each publication. Our analysis to date of publications originating from academia and
industry has identified 152 potent and selective kinase inhibitors (S6 Table) that have activity
on an additional 132 protein kinases (S7 Table) not covered by inhibitors selected from PKIS/
PKIS2. These kinase inhibitors are candidates for inclusion into the KCGS pending permission
to incorporate them, broader screening to standardize selectivity data, and confirmation of a
narrow spectrum selectivity profile when screened across the kinome.
A virtual kinase chemogenomic set
Fig 4 provides examples of compounds from PKIS, PKIS2, and the literature that meet criteria
for inclusion in the KCGS, and examples of compounds that do not warrant inclusion because
of insufficient selectivity.
In total we have identified 390 potential narrow spectrum inhibitors from PKIS, PKIS2, and
the peer-reviewed literature that demonstrate activity on 254/436 of the screenable human
protein kinases (Fig 5). Assembly of these compounds into a single chemogenomic set would
yield a collection of inhibitors that have useful activity on 58% of the currently screenable pro-
tein kinome.
However, there are limitations to this ‘virtual set’ of candidate chemogenomic compounds.
First, many of the compounds have been screened on less than half of the currently available
assays and may not meet our criteria for inclusion in the final set upon broader kinase activity
profiling. Second, some of the published inhibitors may no longer be available in sufficient
quantities for distribution requiring additional chemistry to resynthesize the compounds.
Third, the set still fails to address 42% of the screenable protein kinome. Thus, additional work
is required to reach the goal of building a comprehensive KCGS.
The kinase chemogenomic consortium
To complete the design and construction of a KCGS with complete coverage of the screenable
protein kinome, we have assembled a consortium of academic and industrial partners. The
consortium has the following operating principles:
1. The comprehensive KCGS will be created as an openly available public resource to support
basic research on kinases.
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2. All compounds in the set will be narrow spectrum inhibitors meeting the potency and selec-
tivity criteria defined above.
3. Kinase profiling will be performed using the currently accessible commercial assays, and
the set will be profiled in new assay formats that offer additional information as these
become available (for example, in cell target engagement).
Fig 4. Examples of compounds for the KCGS from (a) PKIS, (b) PKIS2, and (c) the literature that are suitable
(narrow) or not suitable (broad) for inclusion in the KCGS.
https://doi.org/10.1371/journal.pone.0181585.g004
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4. All chemical structures and kinase activity data will be made publically available.
5. The comprehensive KCGS will be made available to all scientists that agree to be trustees of
the set.[48]
The current PKIS/PKIS2/literature virtual set serves as the starting point for development
of the comprehensive KCGS. We started this endeavor in 2016 and asked pharmaceutical com-
pany and academic partners for their ideas and input on set generation (Fig 6).
GSK, Pfizer and Takeda were the first members of the consortium to physically contribute
samples and we anticipate several other pharmaceutical companies and academic labs will con-
tribute to the set in 2017. This year, to start filling the gaps (gap kinases listed in S8 Table), we
have asked current consortium members to identify and provide physical samples of kinase
inhibitors that will cover additional kinases and likely have the requisite potency and selectivity
to be included in the set. Our intent is that this publication serves as a call to all contributors in
the research community to suggest other possible candidates from the literature or their own
research to supplement this work. To be considered for the set the compounds must meet min-
imum criteria:
• Potency–more potent than 100 nM on gap kinase of interest
• Selectivity–profiled against at least 100 kinases with no more than 5% of the screened kinases
more potent than 100 nM or >90% inhibition at 1μM
Fig 5. Representation of the kinome coverage of the virtual set of 457 narrow spectrum inhibitors. Red background shows the human protein kinases
ranked by number of citations. Blue bars show the protein kinases for which an assay is available at one of 10 commercial vendors. Black bars identify
protein kinases that are covered by the virtual set of inhibitors (subset of PKIS, PKIS2, and literature) described in the text.
https://doi.org/10.1371/journal.pone.0181585.g005
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The compounds that we receive physical samples of will be sent for profiling against the
screenable kinome. This will enable direct comparison of compounds in the same set of assays
and conditions to evaluate potency and selectivity, and provide the information needed to
make decisions on what compounds should be included in the final physical set. This data will
also be placed in the public domain.
We realize that inhibitors of suitable quality may not currently exist for some of the un-
covered kinases. For example, inhibitors that do exist for these gap kinases may be too promis-
cuous or not potent enough. This paper is also a call for input from the kinase medicinal
chemistry community on what molecules to synthesize for these uncovered kinases based on
available data and insight. If you can recommend modest starting points for gap kinases
(potency between 100–500 nM; active on 5–15% of the kinome; ideally a chemotype not repre-
sented in PKIS/PKIS2), we would welcome a collaborative effort in which we work together on
synthesis, screening, and funding of the project.
Current members of the consortium include the academic and industrial laboratories rep-
resented as coauthors of this paper. More importantly, membership of the kinase chemoge-
nomic consortium remains open to any scientist who wishes to contribute to the creation of
the comprehensive KCGS as a public resource. Membership in the consortium allows for
access to pre-publication kinase screening data, medicinal chemistry collaboration with our
team, broad kinome screening as required to ensure compound suitability, and a copy of the
complete set, once finalized and created, for screening in phenotypic screens. One of the
Fig 6. Process map for construction of a public comprehensive protein kinase chemogenomic set (KCGS).
https://doi.org/10.1371/journal.pone.0181585.g006
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operating principles of the KCGS is for consortium members to agree to be trustees of the set,
and make decisions around the set with the public good in mind. When recipients sign up to
obtain the KCGS they become a part of this community and agree to place data generated
from screening KCGS into the public domain. This can take many forms–a publication, a pub-
lic database (such as ChemBL and PubChem), or just sending the screening results to the SGC.
As new results become available, the SGC-UNC will post updated records of KCGS publica-
tions and data depositions. Availability of all results from screening the KCGS will be valuable
to future users of the set and for improving KCGS over time. In summary, we welcome contri-
butions of existing kinase inhibitors and submission of ideas for synthesis of new inhibitors
that address any of the gap kinases. Scientists with interest in joining the consortium should
contact David Drewry by email at david.drewry@unc.edu.
Conclusion
Creation of a comprehensive protein kinase chemogenomic set is a large undertaking that can
best be accomplished as a collaborative effort. Importantly, notwithstanding the scale of the
endeavor, it is a tractable problem. The combined effort of medicinal chemists over 20 years of
kinase research has already laid the foundation to the extent that many of the compounds and
much of the data already exist. While no one research group, university, or commercial organi-
zation has access to all of the best inhibitors, together as a community we can pool resources
and knowledge to achieve the goal. Many of the compounds have already been synthesized,
most of the screening assays are commercially available, and importantly there is strong scien-
tific rationale to explore the full human kinome.
The comprehensive KCGS will have it greatest value only if it is freely available as a public
resource. Use of the set in diverse disease relevant phenotypic screens and sharing of the result-
ing data in the public domain is the best mechanism to ensure that the therapeutic potential of
as many protein kinases as possible will be uncovered. This effort will bring to light those
kinases that deserve more detailed drug discovery efforts. Finally, additional incentive to build
this set is provided by the important roles protein kinases have in non-mammalian species.
Although the comprehensive protein kinase chemogenomic set will be designed to explore the
human protein kinases, cross-species homology makes it likely that many of the inhibitors will
have useful activity on parasite[49] and plant kinases[50, 51]. Thus, the work of the consortium
will provide tools for other research sectors, and may lay the groundwork for development of
comprehensive protein kinase chemogenomic sets for these other species.
Looking forward, the opportunity to use chemogenomic sets to explore the biology of other
protein families beyond kinases cannot be overlooked. Analysis of many other druggable pro-
tein families reveals additional examples of the Harlow-Knapp effect: 90% of the research is
focused on only 10% of the proteins[52]. For protein families where chemical connectivity
between inhibitors can be demonstrated, such as phosphodiesterases (PDEs)[53], histone dea-
cetylases (HDACs)[54], bromodomains[55], and non-olfactory G-protein coupled receptors
(GPCRs)[56], we propose that development of publically available chemogenomic sets will be
a profitable approach to expand our biological understanding of the human genome.
Methods
Simulations to estimate adequate set size for full kinome coverage
We conducted a simulation to estimate the theoretical number of compounds required to
achieve kinome coverage under the selectivity criteria set forth herein. To accomplish this, we
integrated over 1 million compound-kinase activity data points collected from the literature
(examples[57–61]) and chemical repositories (PubChem, ChEMBL). We used these data to
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calculate probabilities of co-inhibition at 1 μM potency for pairs of kinases that were repre-
sented in the aggregate dataset. A total of 427 kinases had sufficient profiling data for inclusion
in this exercise. The simulation of a compound’s activity profile began by assigning activity to
a randomly selected kinase, following which the activity was “diffused” to a variable number of
additional kinases. Activity diffusion was constrained by the calculated probabilities of co-
inhibition in order to reflect the pharmacological linkages observed between kinases within
the existing chemical space. Simulated inhibition profiles that targeted 15 kinases at the
computed potency level were appended to the virtual set, provided they did not overlap with
previously incorporated profiles by more than 3 targets, and they did not include targets that
are already inhibited by 5% of the total set of simulated compound profiles. Repeating this
sequence until every kinase was inhibited by at least 3 simulated compounds revealed that an
average of about 571 compounds was sufficient to achieve a set with all the desired attributes.
Increasing the number of kinases from 427 to about 500 will require increasing the number of
compounds to maintain coverage criteria. However, our current results suggest that this
requirement is likely to remain well within the 1000–1500 compound limit.
PKIS2 compound preparation and screening in KINOMEscan
All PKIS2 compounds were dissolved and stored at -20˚C as 10mM DMSO stocks. PKIS2
screening was performed using the commercially available KINOMEscan assay panel as previ-
ously described.[47] These assays are based upon a competition-binding assay that measures
the ability of a small molecule to compete with an immobilized inhibitor for the active site. We
screened the set at 1 μM in singlicate against 468 kinases (including mutants and non-human
kinases). The results are provided as the percentage of the kinase that remains bound to the
immobilized inhibitor relative to a DMSO control (% control). We then converted these num-
bers into percent inhibition (%Inh):
%Inh ¼ 100   %control
Since the assay was only run in singlicate it was important to follow up actives with Kd
determinations. We determined which compounds would get Kd values determined based on
the SI(65), which is the number of kinases bound <65% divided by the total number of assays.
The compounds that had an SI(65) < 0.04 and at least 1 kinase inhibited above 90% were fol-
lowed up by obtaining Kd values for any kinase that was inhibited >80%. Any kinase inhibitor
that had an SI(65) less than 0.04, and was active (< 100nM) on at least 1 kinase in these follow
up Kd experiments, was marked as being a candidate for the KCGS.
PKIS compound selection into the virtual kinase chemogenomic set
PKIS is a set of 367 kinase inhibitors originally profiled against 220 kinases at Nanosyn at 100
nM and 1000 nM.[25] For evaluation of compounds to be included in the chemogenomic set
activity data at 1000 nM was used.
Selectivity Index (SI): For each compound, the SI was assessed at a threshold of 90% kinase




In this equation, SI90 is the selectivity index at 90% inhibition, Nhits is the number of kinases
inhibited by the compound at90%, and Ntotal is the total of kinases against which the com-
pound was tested. It should be noted that the selection of the inhibition threshold is arbitrary
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and will influence the perceived selectivity of the compound. Moreover, kinase panels of differ-
ent sizes should not be directly compared, as the SI is predicated upon Ntotal.
Gini Coefficient: The previously described methodology for the use of the Gini coefficient
to express kinase inhibitor selectivity was followed.[62] In brief, this application of the Gini
coefficient plots the cumulative fraction of total inhibition against the cumulative fraction of
assayed kinases, arranged from least inhibited to most inhibited, and calculates the ratio of the
area between the linear diagonal and cumulative inhibition curve to the area under the linear
diagonal. A linear increase in cumulative inhibition thus results in a value closer to zero and
indicates low selectivity. Compounds with high selectivity, on the other hand, show a slow rise
in cumulative inhibition at the beginning, and a steep rise towards the end (Lorenz curve),
thereby resulting in a Gini coefficient closer to 1. Values closer to 1 indicate “selective” com-
pounds, while values approaching 0 indicate “promiscuous” compounds. It should be noted
that Gini coefficients can be computed regardless of the number of kinases against which the
compound was tested. Thus, the values for any compound can be directly compared.
Entropy Score: The entropy score, previously described by a team at the Netherlands Trans-
lational Research Center to identify selective kinase inhibitors quantifies the distribution of a
compound’s inhibition activity over a panel of kinases, analogous to the distribution of a ther-
modynamic system over multiple energy states.[63] Thus a small entropy score indicates high
selectivity (narrow distribution), while a high entropy score indicates low selectivity (broad
distribution). The score was originally developed for IC50 (or Kd) measurements and was mod-
ified for single-point inhibition data. The following steps were implemented to calculate the
entropy score for each compound within the panel of kinases against which it was tested:




note: if 100% inhibition was the reported result, 99.5%I was used in this calculation
2. Compute Ka values for each kinase by 1/IC50
3. Sum all respective Ka values to generate SKa
4. For each individual Ka value, calculate Ka / SKa
5. For each individual Ka, then calculate (Ka / SKa)
ln(Ka / SKa)
6. Sum each associated value from (5) and multiple by -1 to obtain the resultant entropy score




Selectivity index S(10) at 1 μM: 0<x< 0.02
Potency: At least 1 kinase inhibited >90% Inhibition
If only the Gini measurement criterion was met then for that compound to be considered it
had to inhibit no more than 7 kinases above 90% inhibition at the 1 μM screening concentra-
tion. For purposes of set inclusion only the Nanosyn data was utilized.
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Literature compound selection for the kinase chemogenomic set
Due to the varying assay types and formats that were employed in the literature some basic
rules were followed to identify compounds that have the potential to be included in the KCGS.
For eventual inclusion, systematic broad screening will need to be completed.
Panel size–compound must have been screened against at least 20 other kinases to assess
selectivity; if the panel is small the kinases represented should come from different parts of
the kinome
Potency–must be at least 100 nM or 90% inhibition at 1 μM
Selectivity–must not inhibit more than 10 kinases above 90% inhibition at 1 μM
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